Fenbendazole is a broad-spectrum benzimidazole class anthelmintic that has been used for decades to treat various parasites, including the common roundworm and hookworm. It is also effective against tapeworms.
Unlike most chemotherapy drugs, fenbendazole does not pass through the p-glycoprotein efflux pump that allows cancer cells to adapt and avoid anti-cancer medications. This is one of the main reasons that fenbendazole can effectively destroy cancer and is still effective after chemo-resistance develops.
Fenbendazole is a benzimidazole derivative that acts as a broad-spectrum anthelmintic drug. It is used to treat gastrointestinal parasites, such as giardia, pinworms, roundworms, and hookworms. It can be administered orally (in pill form), or it can be given intravenously.
Several studies have shown that fenbendazole and similar drugs exhibit potent cytotoxicity toward malignant cells and that they may be useful in anticancer therapy. Specifically, fenbendazole has been found to inhibit growth of human lymphoma xenografted into scid mice; it is unclear whether this effect was caused by direct effects on tumor cells or stimulation of host immune responses.
Taking too much fenbendazole can result in serious side-effects, such as severe stomach discomfort or diarrhea. In some people, fenbendazole can also cause liver or kidney damage. Therefore, it is important to follow the dosage instructions carefully. Sanare Lab sells fenbendazole in capsules 222 mg and in pure powder.
The benzimidazole family of medications including fenbendazole is well-tolerated in humans after oral exposure. It is also well tolerated by animals after intravenous administration, but may cause gastrointestinal upset in some pets.
Unlike some chemotherapy medications, resistance to fenbendazole does not develop in cancer cells once it is inside them. This is because the drug does not bind to P-glycoproteins. In addition, fenbendazole makes tumors more sensitive to radiation.
This medicine has a high affinity for lipids in cell membranes, and so it interferes with the way in which a cancer cell absorbs and distributes nutrients. It also prevents the growth of a cancer cell by blocking its ability to synthesize new proteins. This causes the cell to die. This explains why cancer cells are more vulnerable to this medication than normal cells. In addition, fenbendazole does not reduce the effectiveness of other chemotherapy drugs. This was confirmed in experiments where fenbendazole was combined with both radiation and the hypoxia-selective nitroheterocyclic cytotoxins/radiosensitizers in EMT6 mammary tumors in mice.
Fenbendazole is a member of the benzimidazole carbamate family of anti-parasitic drugs. It is a common drug used by veterinarians for anthelmintic purposes in veterinary medicine. It is also used to treat worms and parasites in human beings. It has been approved for use in animals and humans for over six decades.
Because it is metabolized in the liver, some people with severe liver or kidney disease might excrete the medication more slowly. This can create unanticipated side effects. People with this condition might need to take a lower dose or more often.
It is important to tell your doctor and pharmacist about all the medications you are taking, including those you buy without a prescription, as well as herbal supplements and vitamins. Vermox (mebendazole) may interact with some other medicines. This includes antibiotics, antifungals, and some other cancer therapy medications. It also might affect the way other medicines work, such as blood thinners or cyclosporine.
Fenbendazole (also known as Panacur) is a broad-spectrum benzimidazole class anthelmintic drug marketed for gastrointestinal parasites. It exerts its anthelmintic activity by binding to b-tubulin microtubule subunits and disrupting tubulin polymerization. Recently, fenbendazole has been shown to possess antitumor activities in several animal models.
In the laboratory, fenbendazole has stopped glioblastoma tumors from growing in mice by interfering with their ability to metabolize sugar, a process known as glycolysis. It is currently being investigated for its potential to enhance the effectiveness of DCA cancer treatments, as it interferes with a key step in cancer cell metabolism.
This case report describes a patient with advanced nonsmall-cell lung cancer who self-administered oral fenbendazole, based on information she obtained from social media sites about its antitumor activity. Physicians should ask patients about their sources of medical information and be aware that some online resources may contain unproven, possibly dangerous information. They should also inquire about whether patients are taking orally self-administered products and be prepared to assess adverse reactions in the event of unexpected clinical events.sanare lab fenbendazole